Trident Lifeline Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹47.1cr (+50% YoY), EBITDA ₹11.3cr (+65%), PAT ₹6.6cr (+30%). Capacity utilisation 46%. Parenterals facility pending commissioning.
- Call
- Guides 200% growth
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Q2 FY27 consolidated revenue ₹47.1cr (+50% YoY), EBITDA ₹11.3cr (+65%), PAT ₹6.6cr (+30%). Capacity utilisation 46%. Parenterals facility pending commissioning.
Trident Lifeline Ltd reported revenue from operations of ₹80.8 Cr (+62.9% YoY) and net profit of ₹11.7 Cr (+85.7% YoY) for H1 FY27.
Trident Lifeline reported Q2 FY27 revenue of ₹47.1 Cr and PAT of ₹6.6 Cr, up 50% and 30% YoY. The release also mentions a proposed preferential issue.
Trident Lifeline's EGM on 27 October 2026 considered an articles alteration and preferential issues of equity and warrants. E-voting results are due within 48 working hours.
Trident Lifeline declared an interim dividend of Rs 0.50 per share for FY 2026-27. Record date is 30 October 2026, with payment by 25 November 2026.
Trident Lifeline Ltd reported revenue from operations of ₹80.8 Cr (+62.9% YoY) and net profit of ₹11.6 Cr (+58.9% YoY) for H1 FY27.
Trident Lifeline Ltd submitted its quarterly shareholding pattern disclosure in compliance with SEBI regulations. This routine filing presents the distribution of equity across various shareholder categories.
Trident Lifeline Limited scheduled a board meeting for October 26, 2026, to consider financial results for the half year ended September 30, 2026, and interim dividend.
Trident Lifeline has converted 24,000 equity warrants into 24,000 equity shares at a price of Rs. 266 per share, aggregating to Rs. 0.64 Crore.
Trident Lifeline allotted 24,000 equity shares upon conversion of warrants, receiving ₹0.48 Crore. This conversion reduces the number of pending warrants.
Trident Lifeline Limited issued a corrigendum to its EGM notice regarding a Rs.41.14 Crore preferential issue. The update rectifies UBO details and adds disclosures following BSE observations.
Trident Lifeline Limited has issued a corrigendum to its EGM notice regarding a preferential issue of shares and warrants. The amendment provides updated utilization details for proceeds totaling Rs. 57.98 Crore.
Trident Lifeline Limited participated in CPHI Milan 2026, aimed at expanding its presence and visibility in regulated pharmaceutical markets.
Trident Lifeline Ltd corrected clerical errors regarding investor names in Annexure I of the board meeting outcome dated October 5, 2026.
Trident Lifeline Ltd has issued a notice for an Extra-ordinary General Meeting on October 27, 2026, to consider capital issuance and amendments to the company's articles.
Trident Lifeline Ltd has scheduled an EGM for October 27, 2026, to seek approval for an alteration of Articles of Association and a preferential issue of shares.
Trident Lifeline Ltd has submitted its quarterly shareholding pattern as mandated by SEBI regulations for the period ended August 31, 2026.
Trident Lifeline Ltd's board approved a Rs. 57.98 Crore fundraise via preferential allotment of equity shares and convertible warrants. The issue includes shares for public investors and warrants for promoters.
Trident Lifeline Ltd acquired an additional 1% equity stake in its subsidiary, Trident Mediquip Limited, for approximately Rs. 0.95 Crore.
Trident Lifeline has scheduled a board meeting for October 5, 2026, to discuss a potential fund-raising proposal via equity or warrants and to schedule an EGM.
Trident Lifeline Ltd conducted its 13th Annual General Meeting on September 26, 2026, to approve financial statements, director re-appointment, and managerial remuneration proposals.
Trident Lifeline Limited clarified to the stock exchange that recent share price movements are purely market-driven, confirming no pending undisclosed material information.